肝细胞癌的免疫治疗

任正刚

doi:10.3969/j.issn.1001-5256.2018.07.001

肝细胞癌的免疫治疗

DOI: 10.3969/j.issn.1001-5256.2018.07.001

任正刚

复旦大学肝癌研究所

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2301
- HTML全文浏览量: 65
- PDF下载量: 413
- 被引次数: 0
出版历程
- 收稿日期: 2018-06-02
- 出版日期: 2018-07-20

Immunotherapy for hepatocellular carcinoma

Ren ZhengGang

Liver Cancer Institute, Fudan University

摘要

摘要: 在过去的10年里,肝细胞癌(HCC)系统治疗的进步归功于分子靶向治疗的应用及免疫治疗的提高。HCC所处的免疫抑制微环境使肝癌细胞逃逸免疫系统的攻击,这亦为肝癌发展的重要原因,通过提高针对HCC的免疫杀伤能力,纠正免疫抑制状态是HCC免疫治疗的策略。HCC特异性抗原为基础的肿瘤疫苗治疗、基因工程改造的T淋巴细胞治疗、免疫检查点抑制剂的基础研究及临床转化使免疫治疗效果较过去有了显著提高。免疫治疗联合其他抗肿瘤治疗方法如局部消融、分子靶向治疗或肿瘤疫苗等综合治疗模式值得进一步探索。
- 癌,肝细胞 /
- 免疫疗法 /
- 述评
Abstract: In the past 10 years, the progress in systemic therapy for hepatocellular carcinoma ( HCC) is attributed to the application of molecular target therapy and the improvement in immunotherapy. The immunosuppressive microenvironment of HCC enables HCC cells to avoid attack by the immune system, which is also an important reason for the progression of HCC. Improving immune killing of HCC and correcting immunosuppressive conditions are important strategies for immunotherapy for HCC. Tumor vaccine therapy based on HCC specific antigen, genetically engineered T lymphocytes, and basic research and bench-to-bedside translation of immune checkpoint inhibitors have significantly improved the outcome of immunotherapy. Further studies should be performed for immunotherapy combined with other antitumor therapies such as local ablation, molecular targeted therapy, and tumor vaccine therapy.
- carcinoma, hepatocellular /
- immunotherapy /
- editorial

HTML全文

参考文献(13)

[1] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.

[2]MAKAROVA-RUSHER OV, MEDINA-ECHEVERZ J, DUFFY AG, et al.The yin and yang of evasion and immune activation in HCC[J].J Hepatol, 2015, 62 (6) :1420-1429.

[3]CHEW V, LAI L, PAN L, et al.Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J].Proc Natl Acad Sci U S A, 2017, 114 (29) :e5900-e5909.

[4]ZHAO Y, SHUEN TWH, TOH TB, et al.Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy[J].Gut, 2018.[Epub ahead of print]

[5]HU Z, OTT PA, WU CJ.Towards personalized, tumour-specific, therapeutic vaccines for cancer[J].Nat Rev Immunol, 2018, 18 (3) :168-182.

[6]BUONAGURO L, PETRIZZO A, TAGLIAMONTE M, et al.Challenges in cancer vaccine development for hepatocellular carcinoma[J].J Hepatol, 2013, 59 (4) :897-903.

[7]LEE JH, LEE Y, LEE M, et al.A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J].Br J Cancer, 2015, 113 (12) :1666-1676.

[8]LEE JH, LEE JH, LIM YS, et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology, 2015, 148 (7) :1383-1391.

[9]DARGEL C, BASSANI-STERNBERG M, HASREITER J, et al.T Cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice[J].Gastroenterology, 2015, 149 (4) :1042-1052.

[10]JUNE CH, O'CONNOR RS, KAWALEKAR OU, et al.CAR T cell immunotherapy for human cancer[J].Science, 2018, 359 (6382) :1361-1365.

[11]RIBAS A, WOLCHOK JD.Cancer immunotherapy using checkpoint blockade[J].Science, 2018, 359 (6382) :1350-1355.

[12]PATEL SA, MINN AJ.Combination cancer therapy with immune checkpoint blockade:Mechanisms and strategies[J].Immunity, 2018, 48 (3) :417-433.

[13] RIBAS A, DUMMER R, PUZANOV I, et al.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy[J].Cell, 2017, 170 (6) :1109-1119.

施引文献

资源附件(0)

访问统计